BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 15213313)

  • 1. Reducing clinically significant gastrointestinal toxicity associated with nonsteroidal antiinflammatory drugs.
    Jacobsen RB; Phillips BB
    Ann Pharmacother; 2004 Sep; 38(9):1469-81. PubMed ID: 15213313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.
    Chan FK; Graham DY
    Aliment Pharmacol Ther; 2004 May; 19(10):1051-61. PubMed ID: 15142194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonsteroidal anti-inflammatory drugs: add an anti-ulcer drug for patients at high risk only. Always limit the dose and duration of treatment with NSAIDs.
    Prescrire Int; 2011 Sep; 20(119):216-9. PubMed ID: 21954519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention of NSAID induced gastroduodenal ulcers].
    Hansen JM; Bytzer P
    Ugeskr Laeger; 2001 Oct; 163(44):6103-5. PubMed ID: 11715151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
    Goldstein JL; Huang B; Amer F; Christopoulos NG
    Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prophylaxis and therapy of gastropathy caused by non-steroidal anti-inflammatory drugs].
    László A
    Orv Hetil; 2002 Jul; 143(27):1643-8. PubMed ID: 12180001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review.
    Hooper L; Brown TJ; Elliott R; Payne K; Roberts C; Symmons D
    BMJ; 2004 Oct; 329(7472):948. PubMed ID: 15475342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
    Targownik LE; Metge CJ; Leung S; Chateau DG
    Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs.
    McCarthy DM
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):755-73. PubMed ID: 11566039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevention of chronic NSAID induced upper gastrointestinal toxicity: a Cochrane collaboration metaanalysis of randomized controlled trials.
    Rostom A; Wells G; Tugwell P; Welch V; Dubé C; McGowan J
    J Rheumatol; 2000 Sep; 27(9):2203-14. PubMed ID: 10990235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inadequate prevention of NSAID-induced gastrointestinal events.
    Herings RM; Goettsch WG
    Ann Pharmacother; 2004 May; 38(5):760-3. PubMed ID: 15031416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of NSAIDs for the chemoprevention of colorectal cancer.
    Herendeen JM; Lindley C
    Ann Pharmacother; 2003 Nov; 37(11):1664-74. PubMed ID: 14565811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
    Lanas A; Ferrandez A
    Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
    Laine L
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-steroidal anti-inflammatory drug gastropathy: clinical results with H2 antagonists and proton pump inhibitors.
    Lazzaroni M; Bianchi Porro G
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S73-8. PubMed ID: 10379473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention.
    Vonkeman HE; van de Laar MA
    Semin Arthritis Rheum; 2010 Feb; 39(4):294-312. PubMed ID: 18823646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms.
    Laine L
    Rev Gastroenterol Disord; 2003; 3 Suppl 4():S30-9. PubMed ID: 14671512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.